论文标题
基于单细胞RNA测序数据的各种COVID-19培训的可重新定位药物和不良药物反应的鉴定
Identification of Repurposable Drugs and Adverse Drug Reactions for Various Courses of COVID-19 Based on Single-Cell RNA Sequencing Data
论文作者
论文摘要
2019年冠状病毒病（Covid-19）几乎影响了全世界人类生活的每个部分，对人类健康构成了巨大威胁。 Covid-19没有特定的药物，强调迫切需要开发有效的治疗剂。为了识别潜在的可重复药物，我们采用了一种系统的方法来挖掘来自美国FDA批准的药物和临床前小分子化合物的候选者，通过将基因表达的基因表达扰动数据从基于网络的细胞库中的化学物质整合到基于网络的细胞库中的化学物质与公共可用的单细胞rna序列数据库中的综合细胞签名项目中的colect rna序列cocet cocect cole cocect colevid和严重的患者。我们确定了281种FDA批准的药物，这些药物有可能有效抵抗SARS-COV-2感染，其中16例目前正在进行临床试验，以评估其针对COVID-19的功效。我们通过实验测试了Tyrphostin-AG-1478和Brefeldin-A对单链核糖核酸（SSRNA）病毒A型流感病毒的复制的抑制作用。总之，我们使用系统生物学方法确定了可再利用的抗SARS-COV-2药物的列表。
Coronavirus disease 2019 (COVID-19) has impacted almost every part of human life worldwide, posing a massive threat to human health. There is no specific drug for COVID-19, highlighting the urgent need for the development of effective therapeutics. To identify potentially repurposable drugs, we employed a systematic approach to mine candidates from U.S. FDA-approved drugs and preclinical small-molecule compounds by integrating the gene expression perturbation data for chemicals from the Library of Integrated Network-Based Cellular Signatures project with a publicly available single-cell RNA sequencing dataset from mild and severe COVID-19 patients. We identified 281 FDA-approved drugs that have the potential to be effective against SARS-CoV-2 infection, 16 of which are currently undergoing clinical trials to evaluate their efficacy against COVID-19. We experimentally tested the inhibitory effects of tyrphostin-AG-1478 and brefeldin-a on the replication of the single-stranded ribonucleic acid (ssRNA) virus influenza A virus. In conclusion, we have identified a list of repurposable anti-SARS-CoV-2 drugs using a systems biology approach.
